Gene expression changes have been associated with type 2 diabetes mellitus (T2DM); however, the alterations are not fully understood. We investigated the effects of anti-diabetic drugs on gene expression in Zucker diabetic fatty (ZDF) rats using oligonucleotide microarray technology to identify gene expression changes occurring in T2DM. Global gene expression in the pancreas, adipose tissue, skeletal muscle, and liver was profiled from Zucker lean control (ZLC) and anti-diabetic drug treated ZDF rats compared with those in ZDF rats. We showed that anti-diabetic drugs regulate the expression of a large number of genes. We provided a more integrated view of the diabetic changes by examining the gene expression networks. The resulting sub-networks allowed us to identify several biological processes that were significantly enriched by the anti-diabetic drug treatment, including oxidative phosphorylation (OXPHOS), systemic lupus erythematous, and the chemokine signaling pathway. Among them, we found that white adipose tissue from ZDF rats showed decreased expression of a set of OXPHOS genes that were normalized by rosiglitazone treatment accompanied by rescued blood glucose levels. In conclusion, we suggest that alterations in OXPHOS gene expression in white adipose tissue may play a role in the pathogenesis and drug mediated recovery of T2DM through a comprehensive gene expression network study after multi-drug treatment of ZDF rats.
References
[1]
Shoelson SE, Herrero L, Naaz A (2007) Obesity, inflammation, and insulin resistance. Gastroenterology 132: 2169–2180.
[2]
Zimmet P (2000) Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted? J Intern Med 247: 301–310.
[3]
Saltiel AR, Kahn CR (2001) Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414: 799–806.
[4]
Heishi M, Ichihara J, Teramoto R, Itakura Y, Hayashi K, et al. (2006) Global gene expression analysis in liver of obese diabetic db/db mice treated with metformin. Diabetologia 49: 1647–1655.
[5]
Setter SM, Iltz JL, Thams J, Campbell RK (2003) Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin Ther 25: 2991–3026.
[6]
Bailey CJ (2005) Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab 7: 675–691.
[7]
Loffler M, Bilban M, Reimers M, Waldhausl W, Stulnig TM (2006) Blood glucose-lowering nuclear receptor agonists only partially normalize hepatic gene expression in db/db mice. J Pharmacol Exp Ther 316: 797–804.
[8]
Kramer D, Shapiro R, Adler A, Bush E, Rondinone CM (2001) Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats. Metabolism 50: 1294–1300.
[9]
Hsiao G, Chapman J, Ofrecio JM, Wilkes J, Resnik JL, et al. (2011) Multi-tissue, selective PPARgamma modulation of insulin sensitivity and metabolic pathways in obese rats. Am J Physiol Endocrinol Metab 300: E164–174.
[10]
Bogacka I, Xie H, Bray GA, Smith SR (2005) Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes 54: 1392–1399.
[11]
Pardo R, Enguix N, Lasheras J, Feliu JE, Kralli A, et al. (2011) Rosiglitazone-induced mitochondrial biogenesis in white adipose tissue is independent of peroxisome proliferator-activated receptor gamma coactivator-1alpha. PLoS One 6: e26989.
[12]
Koshiba K, Nomura M, Nakaya Y, Ito S (2006) Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. J Med Invest 53: 87–94.
[13]
Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, et al. (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531–537.
[14]
Sreekumar R, Halvatsiotis P, Schimke JC, Nair KS (2002) Gene expression profile in skeletal muscle of type 2 diabetes and the effect of insulin treatment. Diabetes 51: 1913–1920.
[15]
Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, et al. (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34: 267–273.
[16]
Wei D, Li M, Ding W (2007) Effect of vanadate on gene expression of the insulin signaling pathway in skeletal muscle of streptozotocin-induced diabetic rats. J Biol Inorg Chem 12: 1265–1273.
[17]
Tsuda T, Ueno Y, Yoshikawa T, Kojo H, Osawa T (2006) Microarray profiling of gene expression in human adipocytes in response to anthocyanins. Biochem Pharmacol 71: 1184–1197.
[18]
Gerhold DL, Liu F, Jiang G, Li Z, Xu J, et al. (2002) Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-gamma agonists. Endocrinology 143: 2106–2118.
[19]
Kerr MK (2003) Linear models for microarray data analysis: hidden similarities and differences. J Comput Biol 10: 891–901.
[20]
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13: 2498–2504.
[21]
Lee I, Blom UM, Wang PI, Shim JE, Marcotte EM (2011) Prioritizing candidate disease genes by network-based boosting of genome-wide association data. Genome Res 21: 1109–1121.
[22]
Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, et al. (1999) KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 27: 29–34.
[23]
Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 4: P3.
[24]
El-Batran SA, Abdel-Salam OME, Nofal SM, Baiuomy AR (2006) Effect of rosiglitazone and nateglinide on serum glucose and lipid profile alone or in combination with the biguanide metformin in diabetic rats. Pharmacological Research 53: 69–74.
[25]
Sanchez JC, Converset V, Nolan A, Schmid G, Wang S, et al. (2003) Effect of rosiglitazone on the differential expression of obesity and insulin resistance associated proteins in lep/lep mice. Proteomics 3: 1500–1520.
[26]
Reifel-Miller A, Otto K, Hawkins E, Barr R, Bensch WR, et al. (2005) A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia. Mol Endocrinol 19: 1593–1605.
[27]
Edvardsson U, Bergstrom M, Alexandersson M, Bamberg K, Ljung B, et al. (1999) Rosiglitazone (BRL49653), a PPARgamma-selective agonist, causes peroxisome proliferator-like liver effects in obese mice. J Lipid Res 40: 1177–1184.
[28]
Tiikkainen M, Hakkinen AM, Korsheninnikova E, Nyman T, Makimattila S, et al. (2004) Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53: 2169–2176.
[29]
Rong JX, Qiu Y, Hansen MK, Zhu L, Zhang V, et al. (2007) Adipose mitochondrial biogenesis is suppressed in db/db and high-fat diet-fed mice and improved by rosiglitazone. Diabetes 56: 1751–1760.
[30]
Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, et al. (2002) Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51: 2074–2081.
Lessard SJ, Chen ZP, Watt MJ, Hashem M, Reid JJ, et al. (2006) Chronic rosiglitazone treatment restores AMPKalpha2 activity in insulin-resistant rat skeletal muscle. Am J Physiol Endocrinol Metab 290: E251–257.
[33]
Fryer LG, Parbu-Patel A, Carling D (2002) The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 277: 25226–25232.
[34]
Hawley SA, Gadalla AE, Olsen GS, Hardie DG (2002) The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51: 2420–2425.
[35]
DeFronzo RA (1999) Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 131: 281–303.
[36]
Irons BK, Greene RS, Mazzolini TA, Edwards KL, Sleeper RB (2006) Implications of rosiglitazone and pioglitazone on cardiovascular risk in patients with type 2 diabetes mellitus. Pharmacotherapy 26: 168–181.
[37]
Krall RL (2007) Cardiovascular safety of rosiglitazone. Lancet 369: 1995–1996.
[38]
Sehnert AJ, Huq A, Weinstein BM, Walker C, Fishman M, et al. (2002) Cardiac troponin T is essential in sarcomere assembly and cardiac contractility. Nat Genet 31: 106–110.
[39]
Kramer W, Muller G, Girbig F, Gutjahr U, Kowalewski S, et al. (1995) The molecular interaction of sulfonylureas with beta-cell ATP-sensitive K(+)-channels. Diabetes Res Clin Pract 28 Suppl: S67–80
[40]
Muller G, Geisen K (1996) Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at adipocytes. Horm Metab Res 28: 469–487.
[41]
Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, et al. (2003) Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A 100: 8466–8471.
[42]
Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116: 1793–1801.
[43]
Sartipy P, Loskutoff DJ (2003) Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci U S A 100: 7265–7270.
[44]
Cortes S, Chambers S, Jeronimo A, Isenberg D (2008) Diabetes mellitus complicating systemic lupus erythematosus – analysis of the UCL lupus cohort and review of the literature. Lupus 17: 977–980.